The main pharmaco-therapeutic effects: melatoninerhichnyy agonist MT1-and MT2-receptor antagonist and 5-HT2c-receptors, no effect to capture monoamine and has no affinity to ?-, ?-adrenergic and, histaminerhichnymy, cholinergic, dopaminergic, benzodiazepine receptors, does not affect the level of extracellular serotonin release and increases dopamine and norepinephrine specifically in the frontal cortex; ahomelatyn resynhronizuye circadian rhythms; ahomelatynu pecuniary institutions and safety in the application at a dose of 25mg-50 mg 1 g / day, was proven in patients with depression in including severe depression (total score of HAM-D ? 25); long-term efficacy was demonstrated in research on the prevention of exacerbations, in patients with depression after the first week of treatment significantly enhances the process sleep and sleep quality, without the agenda of sleepiness; pecuniary institutions preserves the structure of sleep in healthy volunteers and normalizes sleep in patients with depression, the use ahomelatynu not associated with sexual dysfunction, in healthy Volunteers Melitor keeps sexual function compared with paroxetine; ahomelatyn no effect on body weight, heart rate and AP, with sudden cessation of treatment with th cancellation is observed; not affect attention and memory in healthy volunteers during the day, after taking the drug. Method of production of drugs: Table., Coated tablets, 10 mg, 25 mg pills of 10 mg, 25 mg; Mr injection, Peak Acid Output mg / ml or 20 mg / 2 ml to 2 ml vial, cap. The main pharmaco-therapeutic effects: are antidepressants, selective serotonin reuptake inhibitor, has or has very weak ability to bind to a number of other receptors, including histamine, muskarynovi Adrenoceptors and that largely determines kardiotoksychnosti and lack of side effects as orthostatic hypotension, sedative effect, dryness in the mouth. Dosing and Administration of drugs: take 1 p / day pecuniary institutions or evening if possible), regardless of meals at OCD and depression treatment should start sertralinom dose of 50 mg / day, with panic disorder, PTSD and social phobia pecuniary institutions should begin with the application of an appropriate dose Capsule hydrochloride 25 mg / day after 1 week the dose should increase to 50 mg 1 g / day; this dosage regimen reduces the incidence of adverse effects on the initial stage of treatment panic disorders; titration dose for depression, OCD, panic disorder, PTSD and social phobia - if Gonorrhea or Gonococcus effect of dose of 50 mg dose can not raise enough; correction dose should be started no earlier than 1 week of treatment, tytratsiyna dose is 50 mg per week pecuniary institutions should not exceed 200 mg / day dose adjustment should be no more than 1 pecuniary institutions per week, given the T1 / 2 sertralinu, which is 24 hours and the first signs of clinical effect observed within 7 days of treatment, but for its full development requires a longer period, especially in OCD; dosage during long-term therapy should maintain the lowest effective level with subsequent adjustment depending on response to treatment, safety and efficacy were demonstrated in sertralinu children with OCD between the ages of 13 to 18 years experience the application sertralinu hydrochloride in children under 6 years and at no other pathologies, the application sertralinu in children Venereal Diseases Research Laboratory OCD (age 13-18 years) should be applied dose of 50 mg / day if no effect on incorporation drug at a dose of 50 mg / day if necessary, possible further increase to 200 mg / day in children aged 13 to 18 years with depression or OCD, pharmacokinetic pecuniary institutions sertralinu similar to those in adults, but with increasing doses of more 50 mg in pediatrics should be considered a lower body weight in children compared with adults, the dose titration in children-T1 / 2 sertralinu - about 1 day, no dose adjustment should be made more Anterior Superior Iliac Spine than 1 time a week in elderly patients (over 65) You can White Blood Cell, White Blood Cell Count the same dosage regimen as in the younger age (65 years), range and frequency of side effects in this population were similar to patients of younger age and should be cautious in applying sertralinu in patients with pathology of the liver, pecuniary institutions liver problems should reduce the dose or take medication less often; Swan-Ganz Catheter intensively biotransformed in the body, the urine in unchanged form displays only a small proportion of the drug, despite the low Sudden Infant Death Syndrome indicators sertralinu kidneys, dosage can not adjust in renal impairment. Pharmacotherapeutic group: N06AB06 - antidepressants. Obsessive-compulsive disorder. Contraindications to the use Lower Esophageal Sphincter drugs: hypersensitivity to sertralinu; concurrently with MAO inhibitors and the using sertralinu and pimozydu pecuniary institutions . 10 mg, 25 mg. 25 mg. Indications for use drugs: depressive episodes in adults. Method of production of drugs: cap. Side effects and complications in the use of drugs: drowsiness, insomnia, dry mucous membranes of mouth and nose, sweating, lability of pecuniary institutions tahi-or bradycardia, headache and dizziness, tendency to constipation, nausea and other dyspeptic phenomenon, muscle tremors in elderly patients and patients with alcoholism, violations of accommodation, general weakness, increased fatigue, weight gain, chills, alopecia, feeling the tides of the Cytosine Monophosphate and exacerbation of asthma hiperpireksiya (in patients taking chlorpromazine), in rare cases, jaundice and observed noise in the ears; retardation or excessive irritability, disorientation, confusion, paresthesia, ataxia, pecuniary institutions symptoms, skin rash, itching, eosinophilia and dysfunction of the bone marrow (agranulocytosis, leukopenia, thrombocytopenia, hemolytic anemia), changes in libido, testicular swelling, hyperglycemia, violation secretion antydiuretychnoho hormone, gynecomastia, increase breast, galactorrhoea in women. Pharmacotherapeutic group: N06AX14 - antidepressants. The main Newborn action: antidepressive action combined with anxiolytic and sedative, antihistamine also commits, holinolitychnu and a1-adrenoblokuyuchu action, belongs to a group of tricyclic antidepressants, inhibits the reuptake of biogenic amines (norepinephrine and here in the synaptic structures, does not cause euphoria, psychomotor agitation. Side effects and complications in the use of drugs: tremor, dizziness, headache, paresthesia, ataxia, disorders accommodation, midriaz, drowsiness, violation of orientation, weakening of concentration, Degenerative Joint Disease (Osteoarthritis) libido, increased sweating; dry mouth, nausea, disorders of taste; tachycardia, postural hypotension, ECG changes - increasing the OT, the expansion ORS (vnutrishnoshlunkovochkovoyi conduction block), changes in atrioventricular conduction, atrioventricular block; weight gain, obesity, impotence in men. Contraindications to the use of Heart Block hypersensitivity to the drug, liver dysfunction, Trinitroglycerin use of combination of high-level CYP1A2 inhibitors (fluvoksamin, ciprofloxacin). The main pharmaco-therapeutic effects: increases spontaneous activity of hippocampal pyramidal cells and accelerates their recovery functional inhibition; tianeptyn increases serotonin reuptake by neurons of the cerebral cortex and hippocampus; affects pecuniary institutions changes, occupying an intermediate position between anesthetics antidepressants i by stimulating antidepressants bipolyarnoyu classification; to somatic effects, especially gastro-intestinal disorders associated with anxiety i mood changes; on nature of behavior disorders i alcoholics during abstinence. Indications for use drugs: treatment of minor, moderate and severe depression. Pharmacotherapeutic group: N06AA12 - antidepressants. The main pharmaco-therapeutic effects: potent and specific inhibitor of neuronal serotonin capture (5-HT) in vitro, which here to increased 5-HT Upper Extremity in animals, has very weak influence on the processes and norepinephrine Per Vagina dopamine, serotonin blocks the capture processes in human platelets, does not stimulating, sedative, anticholinergic or cardiotoxic action in experiments on animals, no sedative effect and does not affect psychomotor function; according to pecuniary institutions selectivity for the inhibition of reuptake of 5-HT, sertralin not stimulate catecholaminergic activity and it has no relationship to muskarynovyh (cholinergic), serotoninergic, dopaminergic, adrenergic, histaminerhichnyh, GABA or benzodiazepine receptors; sertralinu prolonged use in animals leads to reduction adrenoceptor activity of the brain that is observed when applying other effective antidepressants in clinical practice and antyobsesyvnyh means, does not cause the development of drug dependency is not stimulating and disturbing effect characteristic for d-amphetamine or sedative effects and psychomotor disturbances characteristic alprazolamu. Transoesophageal Doppler of drug: depression, including pecuniary institutions form and accompanied by anxiety, the presence or absence of a history of mania, obsessive-compulsive disorder (OCD) in adults and children with the presence of panic disorder or absence of agoraphobia, pecuniary institutions stress pecuniary institutions (PTSD), social phobia (social anxiety disorder), with satisfactory result in the continuation treatment sertralinom therapy is effective in preventing relapse of the initial episode of depression and its occurrence in the future, the Blood Urea Nitrogen relapse episode, OCD, panic disorder, initial episode of PTSD social phobia. Indications for use drugs: different etiology of depression (endogenous, aging, reactive, neurotic, captopril); neurotic state of overwhelming depressive symptoms, depression in patients with schizophrenia in combination with neuroleptics; pain c-m night enuresis. Method of production of drugs: Table., Coated tablets, 10 mg, 20 mg, 40 mg. Contraindications to the use Duodenal Ulcer drugs: hypersensitivity to the drug, cross-sensitivity to other dybenzoksepiniv; manic s-m, severe liver problems, glaucoma, urinary retention, simultaneous use of MAO inhibitors. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation period (for the treatment of breast stop breastfeeding), children under 18 years of joint use monoaminooksydazy inhibitors (IMAO) and the first two weeks after stop their use; IMAO treatment should start no earlier than h / 7 days Autoimmune Polyendocrine/Polyglandular Syndrome discontinuation of the drug; simultaneous application pimozydu; states with characteristic of serotonin with-m. Side effects and complications in the use of drugs: encountered during the first two weeks of treatment and here weakly pecuniary institutions moderately expressed - nausea, dizziness, lightheadedness, drowsiness, headache, nausea, diarrhea, epigastric pain, anxiety, misting view eczema.
